01—Abstract
Summary
Summary of the 8-K filed February 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health (CAH) reported second-quarter fiscal 2024 results for the quarter ended December 31, 2023, showing strong top-line and non-GAAP earnings growth alongside a raised full-year non-GAAP EPS outlook.
Revenue rose 12% year over year to $57.4 billiona, led by the Pharmaceutical segment, where revenue grew 12% to $53.5 billion and segment profit rose 12% to $518 million. Non-GAAP operating earnings increased 20% to $562 million and non-GAAP diluted EPS rose 38% to $1.82, helped by higher operating earnings, a lower share count from buybacks, lower interest expense and a lower non-GAAP tax rate. GAAP diluted EPS was $1.43, reflecting the Medical segment's goodwill and asset impairment charges recorded in the prior year and this year's smaller impairment activity.
Management raised fiscal 2024 non-GAAP EPS guidance to $7.20b–$7.35 from $6.75–$7.00 and now targets roughly $2.5 billion of non-GAAP adjusted free cash flow, up from about $2.0 billion. The company also announced a planned acquisition of Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization, and disclosed a preliminary recast of its segments effective January 1, 2024. Under the new structure, the former Medical segment is split between GMPD (Global Medical Products and Distribution, which still carries negative FY23 segment profit) and the Other category, which includes at-Home Solutions.
The former Pharmaceutical segment becomes Pharmaceutical and Specialty Solutions, with a 7%c to 9% segment profit growth outlook. Investors should note that the Medical improvement plan, the ongoing portfolio review, opioid-related litigation and the pending acquisition all carry execution and regulatory risk.
02—Key points
Key Highlights
- Revenue grew 12% year over year to $57.4 billion, with the Pharmaceutical segment contributing $53.5 billion (up 12%) on brand and specialty growth from existing customers.
- Non-GAAP operating earnings rose 20% to $562 million and non-GAAP diluted EPS rose 38% to $1.82, supported by share repurchases, lower interest and other expense and a 21.3% non-GAAP tax rate versus 23.0% a year ago.
- GAAP diluted EPS was $1.43 versus a loss of $(0.50) a year earlier, which included a $709 million goodwill impairment in the Medical segment in Q2 FY23; Q2 FY24 GAAP results included only $1 million in impairments.
- Fiscal 2024 non-GAAP EPS guidance was raised to $7.20–$7.35 from $6.75–$7.00, and non-GAAP adjusted free cash flow guidance was raised to about $2.5 billion from about $2.0 billion.
- Medical segment profit improved to $71 million from $17 million on lower net inflationary impacts, but the fiscal 2024 Medical segment profit outlook was trimmed to about $380 million from about $400 million.
- Cardinal Health agreed to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing organization, and completed a $250 million accelerated share repurchase, bringing year-to-date buybacks to $750 million.
- Segment reporting was restructured effective January 1, 2024, into Pharmaceutical and Specialty Solutions, GMPD and Other, with preliminary FY24 outlooks including Pharmaceutical and Specialty Solutions segment profit growth of 7% to 9%.
03—Questions
Frequently Asked Questions
Why did GAAP EPS swing from a loss to a profit, and is the improvement real?
The swing is largely due to the prior-year quarter, which included a $709 million goodwill impairment on the Medical segment and a large litigation benefit offset. Q2 FY24 GAAP operating earnings of $482 million are much more representative of the underlying business. Non-GAAP EPS growth of 38% is a fairer measure of operating performance, though it excludes recurring items such as amortization and some restructuring costs.
What is driving the raised guidance, and how sustainable is it?
Management attributes the raise to positive operating leverage in the first half, incremental share repurchases beyond baseline plans and a lower expected share count of about 247 million. Pharmaceutical segment profit growth and generics program performance are the main drivers. Sustainability depends on continued Pharmaceutical growth, generic pricing dynamics and whether the Medical Improvement Plan delivers its targeted $650 million of segment profit by FY26.
What does the Specialty Networks acquisition mean for Cardinal Health?
Specialty Networks is a technology-enabled group purchasing and practice enhancement organization for specialty physicians. The deal is intended to expand Cardinal's specialty and healthcare technology capabilities. The filing does not disclose the purchase price, and completion is subject to regulatory approval, with the company warning it may fail to realize the anticipated strategic and financial benefits.
Why was the Medical segment outlook reduced, and what is the company doing about it?
The fiscal 2024 Medical segment profit outlook was lowered to about $380 million from $400 million, even though Q2 profit improved. Management is pursuing the Medical Improvement Plan and has decided to invest in at-Home Solutions and OptiFreight Logistics while continuing a review of Global Medical Products and Distribution. Investors should watch whether the business review leads to divestitures or further impairments.
What are the key risks highlighted in the filing?
Key risks include inflationary pressures, the risk of further Medical goodwill impairment, generic drug deflation, opioid-related settlements and tax challenges, a Department of Justice investigation tied to the anti-diversion program, competitive pressure on contracts, pricing pressure on branded drugs, the execution of the Medical Improvement Plan and the segment restructuring, and the risk that the Specialty Networks acquisition does not close or deliver its expected benefits.
04—Continue